SGS Invests in Genotypic DNA Sequencing System

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-08-03-2016
Volume 11
Issue 8

The company invested in the MicroSeq Rapid Microbial Identification System from Applied Biosystems at its Illinois facility.

On July 12, 2016, SGS announced that it has invested in a genotypic DNA sequencing MicroSeq Rapid Microbial Identification System from Applied Biosystems at its Chicago, IL facility, located in the suburb of Lincolnshire. The molecular identification system is undergoing validation and is expected to be fully implemented in Q3, thus enabling the site to provide accurate, high-speed microbiological testing for the identification of microorganisms. 

The installation and validation of the new genotypic DNA sequencing MicroSeq ID system will minimize transit delays by consolidating testing requirements through a single laboratory, rapidly obtaining identification of bacterial and fungal isolates, and facilitating a rapid response to the investigation of contamination. The investment at SGS’s Chicago site follows recent microbiological testing expansions at the company’s Villeneuve La Garenne, France facility, which provides services to address the growing biopharmaceutical pipeline with capabilities for mycoplasma tests and amino acid analysis, and in Shanghai, China, where a highly active compound laboratory, designed to test products such as antibodies and hormones, is located.

Source: SGS

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content